
SAPA-GP Webinar

Biotech finished 2023 in black, after a turbulent 2023. Going into 2024, people expect tailwinds such as the US interest rate decrease, strong biopharma cash position, and continuous influx of expected major catalysts, as well as the headwinds of incoming presidential election, implementation of IRA and more.
Join our group of biotech veterans who have decades of experiences in entrepreneurship, BD, private investment, public investment, and policies to discuss the key messages from JPM24 and how these messages may impact the outlook of global biotech industry in 2024.
Speakers:
Tong Zhang, Ph.D.
CBO/CFO & Co-Founder
VelaVigo
Jing Yang, Ph.D.
CSO & Co-Founder
BaseCure Therapeutics
Lee Qian, CFA
Investment Manager
Baillie Gifford
Moderator:
Leon ‘Jun’ Tang, Ph.D., M.S.
Founder of InScienceWeTrust
Community
Organizers:

Partners & Collaborators:

| /
★
Date and Time:
Thur, Jan 11, 8:00 PM to 9:00 PM (EST)
Friday, Jan 12, 9:00 AM to 10:00 AM (BJT)
Speakers’ Bio
VelaVigo

Therapeutics



本篇文章来源于微信公众号: 药时代
发布者:haitao.zhao,转载请首先联系contact@drugtimes.cn获得授权